A phase II study evaluating the efficacy and tolerance of combination therapy of imatinib mesylate (IM) + alpha-2A interferon for chronic phase CML [chronic myeloid leukaemia] patients resistant or refractory to IM used as single therapy for at least one year

Trial Profile

A phase II study evaluating the efficacy and tolerance of combination therapy of imatinib mesylate (IM) + alpha-2A interferon for chronic phase CML [chronic myeloid leukaemia] patients resistant or refractory to IM used as single therapy for at least one year

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2007

At a glance

  • Drugs Imatinib (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top